3 surging stocks to buy today?

Should you buy these three major gainers?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

These three companies’ share prices have all risen sharply today. Does this mean it’s too late to buy them, or is there still capital gain potential ahead?

Melrose

Melrose (LSE: MRO) has risen by as much as 13% in Monday trading after it announced that the ‘window shop period’ in respect of its takeover proposal for Nortek expired on 6 August without Nortek having received a superior proposal. Furthermore, all anti-trust conditions in relation to the acquisition have been satisfied, as well as all shareholder resolutions regarding the acquisition. This means that Melrose will now proceed with the acquisition and rights issue, which has been well-received by the market.

Looking ahead, Melrose is forecast to increase its earnings by 25% next year. While impressive, this would still put it on a price-to-earnings (P/E) ratio of 85, which indicates that it’s considerably overpriced. Furthermore, Melrose’s yield of 0.4% provides additional evidence that it lacks a sufficiently wide margin of safety to merit purchase, which means that now may not be the right time to buy it.

Ideagen

Also in the news today is Ideagen (LSE: IDEA). The information management software provider to highly regulated industries has announced the acquisition of Covalent Software for £3.6m. The deal will be funded from Ideagen’s existing cash reserves and with Covalent being profitable and cash generative, it should have a positive impact on Ideagen’s financial performance in future.

The acquisition is in line with Ideagen’s strategy of acquiring complementary businesses with strong intellectual property and recurring revenues. Synergies from the deal are expected to be around £0.18m per annum as well as an initial £0.1m, with the combined entity having a stronger position in the NHS, local government and financial services verticals.

Looking ahead, Ideagen is forecast to increase its earnings by 8% this year and by a further 10% next year. This puts it on a price-to-earnings growth (PEG) ratio of 1.6, which indicates that it offers good value for money. As such, its shares could continue their 20% rise over the last 12 months.

IGAS

IGAS (LSE: IGAS) has surged 32% higher today after Theresa May suggested that people affected by fracking could be paid compensation directly. Although no hard and fast figures have been released, it could be as much as £10,000 per household and this would be a significant shift in policy since compensation was previously expected to be paid to local councils.

This could prove to be good news for IGAS since it shows that the government appears to be committed to fracking over the long term. It means that IGAS’s share price has now risen by over 50% in the last month and while it remains a relatively risky buy, it could continue this run over the medium-to-long term as external factors appear to be increasingly favourable.

Clearly, IGAS is highly dependent on news flow, but with its latest results showing that its leverage is falling and its costs remain manageable at $30 per barrel of oil equivalent (boe), it could be a sound buy for less risk-averse investors.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK owns shares of Melrose. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »